Impact of loading phase, initial response and cfh genotype on the long-term outcome of treatment for neovascular age-related macular degeneration

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Menghini, Moreno ^a   Kloeckener Gruissem, Barbara ^b,c   Fleischhauer, Johannes ^a   Kurz Levin, Malaika M ^a   Sutter, Florian K P ^a   Berger, Wolfgang ^b   Barthelmes, Daniel ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CFH GENE; FEMALE; GENE; GENE ACTIVITY; GENE FUNCTION; GENETIC ANALYSIS; GENOTYPE; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RETINA MACULA AGE RELATED DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM; SWITZERLAND; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COMPLEMENT FACTOR H; FEMALE; GENOTYPE; HUMANS; MACULAR DEGENERATION; MALE; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864328535     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042014     Document Type: Article

References (34)

1. Bressler NM, (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291: 1900-1901.
2. Taylor HR, Keeffe JE, Vu HT, Wang JJ, Rochtchina E, et al. (2005) Vision loss in Australia. Med J Aust 182: 565-568.
3. VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, et al. (2000) The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 107: 1593-1600.
4. Wang JJ, Rochtchina E, Lee AJ, Chia EM, Smith W, et al. (2007) Ten-year incidence and progression of age-related maculopathy: the blue Mountains Eye Study. Ophthalmology 114: 92-98.
5. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, et al. (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39: 367-374.
6. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
7. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, et al. (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444.
8. Menghini M, Kurz-Levin MM, Amstutz C, Michels S, Windisch R, et al. (2010) Response to ranibizumab therapy in neovascular AMD- an evaluation of good and bad responders. Klin Monbl Augenheilkd 227: 244-248.
9. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, et al. (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148: 43-58 e41.
10. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, et al. (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145: 239-248.
11. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prunte C, et al. (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94: 2-13.
12. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, et al. (2010) The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 51: 405-412.
13. Gupta B, Adewoyin T, Patel SK, Sivaprasad S, (2011) Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Br J Ophthalmol 3: 386-90.
14. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897-1908.
15. Gerding H, Loukopoulos V, Riese J, Hefner L, Timmermann M, (2011) Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol 249: 653-662.
16. Heimes B, Lommatzsch A, Zeimer M, Gutfleisch M, Spital G, et al. (2011) Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol 249: 639-644.
17. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, et al. (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118: 663-671.
18. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, et al. (2011) Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study. Ophthalmology 118: 831-839.
19. Swaroop A, Branham KE, Chen W, Abecasis G, (2007) Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet 16 Spec No. 2: R174-182.
20. Tuo J, Bojanowski CM, Chan CC, (2004) Genetic factors of age-related macular degeneration. Prog Retin Eye Res 23: 229-249.
21. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, et al. (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419-421.
22. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, et al. (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102: 7227-7232.
23. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389.
24. Kloeckener-Gruissem B, Barthelmes D, Labs S, Schindler C, Kurz-Levin M, et al. (2011) Genetic association with response to intravitreal ranibizumab (Lucentis(R)) in neovascular AMD patients. Invest Ophthalmol Vis Sci 52: 4694-702.
25. McKibbin M, Ali M, Bansal S, Baxter PD, West K, et al. (2012) CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 96: 208-12.
26. Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E, (2010) Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 16: 2598-2604.
27. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr, (2009) Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 93: 610-613.
28. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, et al. (2007) Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114: 2168-2173.
29. Tsuchihashi T, Mori K, Horie-Inoue K, Gehlbach PL, Kabasawa S, et al. (2011) Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology 118: 93-100.
30. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, et al. (2009) A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116: 1731-1739.
31. Ormsby RJ, Ranganathan S, Tong JC, Griggs KM, Dimasi DP, et al. (2008) Functional and structural implications of the complement factor H Y402H polymorphism associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 49: 1763-1770.
32. Laine M, Jarva H, Seitsonen S, Haapasalo K, Lehtinen MJ, et al. (2007) Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 178: 3831-3836.
33. Bressler SB, (2009) Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 116: S1-7.
34. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HP, et al. (2011) Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478: 76-81.